Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IL-2 neuropsychiatric symptoms: mechanism and prevention

Trial Profile

IL-2 neuropsychiatric symptoms: mechanism and prevention

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2018

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Depression
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top